Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Chronic Myeloid Leukemia

Study Title

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Teva Identifier

CGX-635-CML-202 | 2006-000176-32

ClinicalTrials.gov Identifier

NCT00375219

Study Status

Completed

Trial Condition(s)

Chronic Myeloid Leukemia

Interventions

Drug: Omacetaxine mepesuccinate

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Click for participation criteria and map of study locations
cancer icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years and older

Trial Duration

09/01/2006 - 09/01/2013

Phase

Phase 2

Study Type

Interventional